Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines
- 14 June 2022
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (13), e0038322
- https://doi.org/10.1128/jvi.00383-22
Abstract
Despite the rapid deployment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, the emergence of SARS-CoV-2 variants and reports of their immune evasion characteristics have led to an urgent need for novel vaccines that confer potent cross-protective immunity. In this study, we constructed three different SARS-CoV-2 spike S1-conjugated nanoparticle vaccine candidates that exhibited high structural homogeneity and stability. Notably, these vaccines elicited up to 50-times-higher neutralizing antibody titers than the S1 monomer in mice. Crucially, it was found that the S1-conjugated nanoparticle vaccine could elicit comparable levels of neutralizing antibodies against wild-type or emerging variant SARS-CoV-2, with cross-reactivity to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), the effect of which could be further enhanced using our designed nanoparticles. Our results indicate that the S1-conjugated nanoparticles are promising vaccine candidates with the potential to elicit potent and cross-reactive immunity against not only wild-type SARS-CoV-2, but also its variants of concern, variants of interest, and even other pathogenic betacoronaviruses. IMPORTANCE The emergence of SARS-CoV-2 variants led to an urgent demand for a broadly effective vaccine against the threat of variant infection. The spike protein S1-based nanoparticle designed in our study could elicit a comprehensive humoral response toward different SARS-CoV-2 variants of concern and variants of interest and will be helpful to combat COVID-19 globally. The emergence of SARS-CoV-2 variants led to an urgent demand for a broadly effective vaccine against the threat of variant infection. The spike protein S1-based nanoparticle designed in our study could elicit a comprehensive humoral response toward different SARS-CoV-2 variants of concern and variants of interest and will be helpful to combat COVID-19 globally.Keywords
Funding Information
- National Natural Science Foundation of China (82030046)
This publication has 78 references indexed in Scilit:
- Secrets of a covalent interaction for biomaterials and biotechnology: SpyTag and SpyCatcherCurrent Opinion in Chemical Biology, 2015
- On the Mechanism Determining the Th1/Th2 Phenotype of an Immune Response, and its Pertinence to Strategies for the Prevention, and Treatment, of Certain Infectious DiseasesScandinavian Journal of Immunology, 2014
- Nanoparticle vaccinesVaccine, 2014
- Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodiesNature, 2013
- Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesinProceedings of the National Academy of Sciences of the United States of America, 2012
- Safety of MF59™ adjuvantVaccine, 2008
- Epitope MappingBioDrugs, 2007
- Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro modelInternational Journal of Pharmaceutics, 2005
- Regulation of antibody isotype secretion by subsets of antigen-specific helper T cellsNature, 1988
- Interferon-γ and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype ProductionScience, 1987